Characterization of Pd-L1 in a Barrett's Esophageal Adenocarcinoma Cell Culture Model
ISEF · 2024 Biomedical and Health Sciences
Overview
Introduction While the incidence of esophageal adenocarcinoma is rapidly increasing, the prognosis remains poor with a five-year survival rate of 20%. Therefore, the discovery of new molecular targets is necessary for efficient characterization of oesophageal adenocarcinoma patients. PD-L1, which is overexpressed in many cancers, may also play a role in the treatment of esophageal adenocarcinoma. Materials and methods Barrett's esophagus cells were analyzed for PD-L1, CD86 and HLA-ABC expression in an in vitro model. The cells were treated with chemotherapeutic agents (5-FU, cisplatin and oxaliplatin) and inhibitors targeting immune checkpoints (nivolumab and atezolizumab). Proliferation and expression levels were analyzed. Results While squamous, metaplastic and dysplastic cells showed low PD-L1 expression, oesophageal adenocarcinoma cells showed heterogeneous expression. The highest PD-L1 expression was found in OE33 cells, while OE19 cells showed no PD-L1 expression. OE33 cells treated with 5-FU, cisplatin and oxaliplatin showed increased PD-L1, CD86 and HLA-ABC expression. Proliferation was reduced by 10-20% in OE33 and OE19 cells after treatment with nivolumab and atezolizumab. Conclusion PD-L1 is an important target molecule that is also overexpressed in adenocarcinomas of the esophagus and in the OE33 cell line. Due to the heterogeneous expression of PD-L1 in the different cell lines, it is necessary to test the PD-L1 level prior to therapy. Impairment of PD-L1 by conventional chemotherapeutic agents has been shown in Barrett's esophagus carcinoma cells. Since PD-L1 expression is impaired by conventional chemotherapeutic agents, future studies should also pay attention to altered PD-L1 levels under therapy.
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2023
Immune Checkpoint Regulation in Molecular Subtypes of Endometrial Cancer: Expression of PD-L1 and PD-1
ISEF · 2023
The Effect of Nicotinamide on the Il-6 Expression and Cell Count of Barrett's Esophagus Expressing Cells
ISEF · 2021
Identification and Analysis of Key Candidate Genes and Pathways in Lung Adenocarcinoma by Integrated Bioinformatics
ISEF · 2017
Necrosis of Lung Adenocarcinoma by Targeting a Novel Egg-Specific Protein
ISEF · 2024
Validating and Evaluating Expression of New Tumor Targets Across Cancers: Protein X as a Potential Target for Cancer Drug Development
ISEF · 2021
Synergy of Treatment: Therapeutic Vulnerabilities in Small Cell Lung Cancer
ISEF · 2016
Identification and Characterization of Novel Diagnostic and Therapeutic Targets in Pancreatic Ductal Adenocarcinoma Using an Antibody-Based Approach
JSHS · 2020
The effect of anti-PD1 and anti-PDL1 on the cytokine profile and immune system
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair